{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"CBR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"SD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"The proportion of patients demonstrating a clinical benefit (CBR) complete response + partial response + stable disease rates) based on RECIST v1.1.","groups":[{"description":"Everolimus 10 mg PO daily + Letrozole 2.5 mg PO daily + Metformin 500 mg PO twice daily on a 4 week schedule","id":"OG000","title":"Rad-Let-Met"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"54 participants were evaluable","reportingStatus":"POSTED","timeFrame":"93 months","title":"Clinical Benefit (CBR) Complete Response + Partial Response + Stable Disease Rates) Based on RECIST v1.1.","type":"PRIMARY","unitOfMeasure":"Participants"}